Novartis AG v Hospira UK Ltd, England and Wales Court of Appeal (Civil Division), Judgment, Law, casemine.com

Citation Codes

Equivalent Citations

citation codes

Advocates

Justin Turner QC and James Whyte (instructed by Bristows) for the Appellant
Adrian Speck QC and Tom Mitcheson (instructed by Taylor Wessing) for the Respondent

Judges

LORD JUSTICE LEWISON
LORD JUSTICE KITCHIN
LORD JUSTICE FLOYD

See more information ...

Click here to read the full judgment

Novartis AG v. Hospira UK Ltd

Smart Summary

Factual and Procedural Background

The appeal concerns an interim injunction application by Company A following a judgment by Birss J refusing such relief in a patent infringement action pending an appeal. Company A owns two European patents covering the use of zoledronic acid for treating osteoporosis, associated with their drug product. The patents were challenged in revocation proceedings initiated by Company B, a generic medicine manufacturer intending to launch a generic product. The revocation trial took place and the patents were held invalid on grounds including priority and insufficiency. The Supplementary Protection Certificate (SPC) covering zoledronic acid expired shortly after the trial. Company A sought an interim injunction to restrain Company B from launching its generic product pending appeal, but the injunction was refused by Birss J. Company A appealed that refusal, prompting this urgent appeal hearing due to Company B's imminent product launch.

Legal Issues Presented

Whether an interim injunction pending appeal should be granted when the patent in suit has been held invalid at first instance.
The principles governing the grant of interim injunctive relief pending appeal, particularly in patent cases where the claimant has lost at trial.
How the balance of convenience and potential unquantifiable harm to the parties should be assessed in the context of an appeal from a judgment invalidating patents.
The relevance and weight to be accorded to procedural history and communications between the parties, including undertakings and scheduling of trial and appeal dates, when considering interim relief pending appeal.

Arguments of the Parties

Appellant's Arguments

The judge erred in treating the decision on the merits as affecting the balance of convenience for interim relief pending appeal.
The judgment of invalidity does not constitute a "clear view on the merits" that should weigh against granting interim relief.
The letter dated 18 December 2012 should not have been given significant weight to the detriment of Company A.
Company A contended that the appeal had a realistic prospect of success, particularly on the issue of priority, which is a question of document construction rather than factual findings.
It was inappropriate to place a burden on Company A to have expedited the trial or appeal process before becoming aware of Company B’s marketing authorisation and launch intentions.

Appellee's Arguments

The judge was correct to consider the merits decision as a significant factor in the balance of convenience.
Company B had a real risk of losing the "first mover advantage" if the injunction were granted, which was a substantial harm.
Company B’s marketing authorisation included indications (such as Paget's disease) not covered by the patents, and the injunction would unreasonably restrain sales for these lawful uses.
Company A had a related company with generic marketing authorisation, mitigating potential losses, so the risk of price cutting was overstated.
It was unreasonable and against public interest to require generic manufacturers to initiate litigation so far in advance of launch dates, as this would deter market entry and delay access to lower-cost medicines.
The public interest favored allowing generic entry to reduce medicine costs, and cross-undertakings offered by Company A would not fully compensate the National Health Service for any damages.

Table of Precedents Cited

Precedent	Rule or Principle Cited For	Application by the Court
American Cyanamid v Ethicon [1975] AC 396	Principles governing the grant of interlocutory injunctions including balance of convenience and risk of irreparable harm.	The court applied these principles to assess whether an interim injunction would have been appropriate pre-trial and considered how the balance changes post-judgment.
Minnesota Mining v Johnson and Johnson [1976] RPC 671	Discretion to grant or stay injunctions pending appeal and balancing interests of parties to achieve justice.	Guided the court’s approach to interim relief pending appeal, emphasizing the need for a real prospect of success and consideration of damages undertakings.
Servier v Apotex (unreported, 6 July 2007)	Application of American Cyanamid principles to injunctions pending appeal where the claim failed at trial.	Supported the proposition that a good arguable appeal is required and that interim relief pending appeal should be considered on similar principles as pre-trial injunctions.
Pozzoli v BDMO SA [2007] EWCA Civ 588	Consideration of prospects of success on appeal as relevant to interim relief.	Referenced in Servier for the approach to appeals and injunctions pending appeal.
Ketchum International v Group Public Relation Holdings [1997] 1 WLR 4	Application of "good arguable case" test for Mareva injunctions and its analogy to interim relief pending appeal.	Supported the court’s application of a high threshold for good arguable appeal before granting interim relief.
Guardian Group v Associated Newspapers (unreported CA 20 January 2000)	Weight to be given to clear views on merits when granting interim relief.	The court considered but distinguished the case as a passing off claim, noting less need to delve into merits in patent cases for interim relief.
Virgin Atlantic Airways v Premium Aircraft Interiors [2009] EWCA Civ 1513	Balance of convenience principle in injunctions pending appeal and differences from injunctions pending trial.	Confirmed that successful patentees generally obtain injunctions pending appeal subject to cross-undertakings and balance of convenience.
Polini v Gray (1879) 12 Ch. D 438	Principle that litigation is not at an end until all appeals are disposed of and courts may stay orders accordingly.	Supported the view that parties should expect litigation to continue through appeals, affecting interim relief considerations.
Smithkline Beecham v Apotex (unreported CA 23 October 2001)	Necessity for generic manufacturers to clear patent obstacles before launching products.	Reinforced the common sense approach that generics should anticipate patent litigation and plan accordingly.

Court's Reasoning and Analysis

The court began by acknowledging the established jurisdiction to grant interim relief pending appeal, emphasizing that such relief is discretionary and requires a real prospect of success on appeal. Drawing on precedent, the court explained that the principles for injunctions pending appeal are similar to those at the interlocutory stage, but the balance of convenience shifts once a trial judgment has been delivered.

The court rejected the lower judge’s approach of giving significant weight to the trial judgment as a "clear view on the merits," noting that both trial and appellate judges considered the appeal to have a realistic prospect of success. The court held that the discretion should not be exercised on the basis that the merits decisively favor one side.

Regarding the letter dated 18 December 2012, the court found it was wrongly given weight as evidence of a tacit understanding that the trial judgment would determine Company B’s freedom to launch post-SPC expiry. The letter was aimed at clarifying undertakings if the patents were held valid, not invalid.

The court considered the balance of unquantifiable harm to each party. It found that the potential damage to Company A from loss of monopoly pricing and reputation was more certain and of greater magnitude than the risk to Company B of losing first mover advantage, especially given the presence of other generic competitors.

Public interest arguments favoring generic entry and earlier litigation were acknowledged but found insufficient to outweigh the harm to Company A. The court emphasized that appeals are common in pharmaceutical patent litigation and that generic manufacturers should plan for appeals and disclose launch intentions early enough to allow expedited proceedings if necessary.

On this basis, the court concluded that the balance of convenience favored granting an interim injunction pending appeal to restrain Company B’s launch of the generic product.

Holding and Implications

The court ALLOWED THE APPEAL and granted an interim injunction restraining Company B from launching its generic zoledronic acid product in the UK pending the outcome of the appeal or further order.

The direct effect is to maintain Company A’s monopoly position temporarily pending appellate review, preventing Company B from entering the market immediately after SPC expiry. The decision does not establish new legal precedent but clarifies the application of existing principles governing interim injunctions pending appeal in patent cases where the patent has been held invalid at first instance. It underscores the importance of balancing unquantifiable harm and the realistic prospects of success on appeal without over-weighting the trial judgment against the appellant.